Neoadjuvant immunotherapy improves outlook in high-risk melanoma

Belgique Nouvelles Nouvelles

Neoadjuvant immunotherapy improves outlook in high-risk melanoma
Belgique Dernières Nouvelles,Belgique Actualités
  • 📰 medical_xpress
  • ⏱ Reading Time:
  • 62 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 28%
  • Publisher: 51%

Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery.

To test this hypothesis, S1801 investigators enrolled 345 participants with stage IIIB through stage IV melanoma that was deemed operable. Participants ages 18-90 were randomized to receive either upfront surgery followed by 200 mg of pembrolizumab every three weeks for a total of 18 doses, or to 200 mg of pembrolizumab every three weeks for three doses leading up to surgery , then an additional 15 doses following surgery.

The primary endpoint measured was the duration of event-free survival, defined as the time from randomization to the occurrence of one of the following:or toxicity that resulted in not receiving surgery, failure to begin adjuvant therapy within 84 days of surgery, melanoma recurrence after surgery, or death from any cause.

With a median follow-up of 14.7 months, event-free survival was significantly longer in the neoadjuvant therapy arm, with a hazard ratio of 0.58 when compared to the adjuvant therapy arm, which corresponds to a 42% lower event rate in the patients receiving the neoadjuvant regimen. "Our study noted a significant improvement in event-free survival in the neoadjuvant regimen compared to the adjuvant regimen," Patel said."Importantly, a similar number of patients in both arms experienced events before initiating adjuvant pembrolizumab, but the rate of eventsThe researchers found that the benefit from neoadjuvantwas consistent across a range of factors including patient age, sex, performance status, and stage of disease.

"Based on the findings from S1801, patients with high-risk melanoma should start immunotherapy prior to surgery to generate an

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

medical_xpress /  🏆 101. in UK

Belgique Dernières Nouvelles, Belgique Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

How improving the way you breathe can improve performance and change your lifeHow improving the way you breathe can improve performance and change your lifeAnd breathe 🧘‍♀️ Improving your breathwork, with these tips and tricks could enhance your performance and change your life!
Lire la suite »

Your guide to enjoying yourself in Monton: One of the most up-and-coming suburbsYour guide to enjoying yourself in Monton: One of the most up-and-coming suburbsCosy brunch spots, buzzing cocktail bars and a butcher's shop inspired by the delis of Rome - the lesser-known Greater Manchester suburb on the up
Lire la suite »

China’s government bites down on expensive mooncakesChina’s government bites down on expensive mooncakesMooncakes have long been associated with graft. Businesses seeking favours from the government often send officials fancy boxes full of the pastry—and other, more expensive goodies
Lire la suite »

Ferrari chairman backs Binotto but F1 team "needs to improve"Ferrari chairman backs Binotto but F1 team "needs to improve"🗣'We have great faith in Mattia Binotto' Ferrari chairman John Elkann has backed the F1 team's current boss, but has urged it to improve as 'too many mistakes' have been made. Story:
Lire la suite »

A more sober outlook weighs on investors\n\t\t\tExpert insights, analysis and smart data help you cut through the noise to spot trends,\n\t\t\trisks and opportunities.\n\t\t\n\t\tJoin over 300,000 Finance professionals who already subscribe to the FT.
Lire la suite »



Render Time: 2025-04-04 18:57:11